Lundbeck strikes $250M Abide buyout, bagging Tourette's drug

Lundbeck strikes $250M Abide buyout, bagging Tourette's drug

Source: 
Fierce Biotech
snippet: 

Lundbeck is set to pay $250 million (€223 million) up front to buy Abide Therapeutics. The deal will give Lundbeck a phase 2a Tourette's syndrome program, a CNS drug discovery platform and a West Coast research hub.